2,2-二甲基-4-乙烯基-1,3-二氧戊环 | 83968-02-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2,2-二甲基-4-乙烯基-1,3-二氧戊环
• 英文名称: 2,2-dimethyl-4-vinyl-1,3-dioxolane
• 英文别名: 4-ethenyl-2,2-dimethyl-1,3-dioxolane
• CAS: 83968-02-9
• 化学式: C₇H₁₂O₂
• mdl: MFCD00142768
• 分子量: 128.171
• InChiKey: SQXNZBLNWGWIHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2932999099

SDS

Name:	2 2-Dimethyl-4-ethenyl-1 3-dioxolane Material Safety Data Sheet
Synonym:
CAS:	83968-02-9

Section 1 - Chemical Product MSDS Name:2 2-Dimethyl-4-ethenyl-1 3-dioxolane Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
83968-02-9	2,2-dimethyl-4-ethen		unlisted

Hazard Symbols: Not available.
Risk Phrases:

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower lids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes.
Remove contaminated clothing and shoes.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire.
Autoignition Temperature: Not available.
Flash Point: Not available.
NFPA Rating: Not published.
Explosion Limits, Lower: Not available.
Upper: Not available.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Avoid contact with eyes, skin, and clothing. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Keep container closed when not in use.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use process enclosure, local exhaust ventilation, or other engineering controls to control airborne levels.
Personal Protective Equipment Eyes: Wear chemical goggles.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to minimize contact with skin.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions warrant a respirator's use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Not available.
Appearance: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Vapor Density: Not available.
Evaporation Rate: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 0 deg C
Decomposition Temperature: Not available.
Solubility: Not available.
Specific Gravity/Density: Not available.
Molecular Formula: C7H12O2
Molecular Weight: 128.17

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, strong oxidants.
Incompatibilities with Other Materials:
Not available.
Hazardous Decomposition Products:
Irritating and toxic fumes and gases.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 83968-02-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,2-dimethyl-4-ethen - Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA.
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION
For further information, contact Fisher Scientific.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

CDG/CPL
IMO
Not regulated as a hazardous material.
IATA
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.
Canadian TDG
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 83968-02-9:
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
WHMIS: Not available.
CAS# 83968-02-9 is not listed on Canada's Ingredient Disclosure List.
Exposure Limits
US FEDERAL
TSCA
CAS# 83968-02-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,2-二甲基-4-乙烯基-1,3-二氧戊环 在 lithium aluminium tetrahydride 、 异氰酸苯酯 、 三乙胺 作用下， 以 乙醚 、 苯 为溶剂， 反应 313.0h， 生成 D-ribo-2-amino-2,3-dideoxy-5,6-O-isopropyliden-hexose neopentyl glycol acetal
  参考文献：
  名称：

  由4-乙烯基-1,3-二氧戊环和硝基乙醛缩醛通过异恶唑啉DL-和D-碘胺（2-氨基-2,3-二脱氧-核糖-己糖）衍生物合成氨基糖

  摘要：

  氧化腈的1,3-偶极环加成，从硝基乙醇和nitroacetaldehyde衍生物产生的3,21和22，分别和苄腈氧化物4- vinyldioxolanes 1,2给CA 4:1赤式/苏式对应异恶唑啉的混合物。的LAH还原erytho异恶唑啉继续进行类似（CA 4：1）选择性配料受保护的核糖-氨基-多元醇11，15,19，和DL- d-lividosamines 31和33分别作为主产品。DL-李维糖胺衍生物33通过结晶获得纯产物。在D系列中，将相应的核糖/阿拉伯糖混合物D- 31 / D- 32转化为已知的α-甲基D-脂维糖胺D- 37。

  DOI：

  10.1016/0040-4020(84)80002-2
• 作为产物：
  描述：

  2-(2,2-dimethyl-1,3-dioxolan-4-yl)ethyl 4-methylbenzenesulfonate 在 bis(4-chlorophenyl)selenide 、 双氧水 作用下， 生成 2,2-二甲基-4-乙烯基-1,3-二氧戊环
  参考文献：
  名称：

  Malanga, Corrado; Menicagli, Rita; Lardicci, Luciano, Gazzetta Chimica Italiana, 1992, vol. 122, # 1, p. 45 - 50

  摘要：

  DOI：

文献信息

• Macrocyclic MCL-1 inhibitors and methods of use
  申请人：AbbVie Inc.

  公开号：US20190055264A1

  公开（公告）日：2019-02-21

  The present disclosure provides for compounds of Formula (I) wherein A 2 , A 3 , A 4 , A 6 , A 7 , A 8 , A 15 , R A , R 5 , R 9 , R 10A , R 10B , R 11 , R 12 , R 13 , R 14 , R 16 , W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

  本公开提供了Formula (I)的化合物，其中A2、A3、A4、A6、A7、A8、A15、RA、R5、R9、R10A、R10B、R11、R12、R13、R14、R16、W、X和Y具有规范中定义的任何值，以及其药学上可接受的盐，可用作治疗疾病和病况的药物，包括癌症。还提供了包含Formula (I)化合物的药物组合物。
• ALDEHYDE-SELECTIVE WACKER-TYPE OXIDATION OF UNBIASED ALKENES
  申请人：CALIFORNIA INSTITUTE OF TECHNOLOGY

  公开号：US20140316149A1

  公开（公告）日：2014-10-23

  This disclosure is directed to methods of preparing organic aldehydes, each method comprising contacting a terminal olefin with an oxidizing mixture comprising: (a) a dichloro-palladium complex; (b) a copper complex; (c) a source of nitrite; under aerobic reaction conditions sufficient to convert at least a portion of the terminal olefin to an aldehyde.

  这份披露涉及制备有机醛的方法，每种方法包括将末端烯烃与包括： (a) 二氯化钯络合物； (b) 铜络合物； (c) 亚硝酸盐源； 的氧化混合物接触，在充分的氧化反应条件下，将至少部分末端烯烃转化为醛。
• Protein-tyrosine phosphatase inhibitors and uses thereof
  申请人：——

  公开号：US20040214870A1

  公开（公告）日：2004-10-28

  The present invention is directed to compounds of formula (I), 1 or a pharmaceutically suitable salt or prodrug thereof, which are useful for the selective inhibition of protein tyrosine phosphatase-1B (PTP1B), and are useful for the treatment of disorders caused by overexpressed or altered protein tyrosine phosphatase 1B.

  本发明涉及式(I)的化合物，或其药用适宜盐或前药，用于选择性抑制蛋白酪氨酸磷酸酶-1B（PTP1B），并且用于治疗由过度表达或改变的蛋白酪氨酸磷酸酶1B引起的疾病。
• [EN] A PROCESS FOR THE PREPARATION OF AN ALDEHYDE BETA-LACTAM COMPOUND<br/>[FR] PROCÉDÉ DE PRÉPARATION D'UN COMPOSÉ BÊTA-LACTAME D'ALDÉHYDE
  申请人：ADAMED SP ZOO

  公开号：WO2010097350A1

  公开（公告）日：2010-09-02

  The invention relates to a process for the preparation of an aldehyde beta-lactam compound of formula (I), wherein P1 is H or a protecting group, useful in the preparation of ezetimibe, from a nitrone compound of formula (II). The nitrone compound Il is prepared by reacting 4-fluorophenylhydroxyloamine with OH- protected 4-hydroxybenzaldehyde. The nitrone compound of formula (II) is reacted with an acetylene compound of formula (III) to form a compound of formula (IV), and the compound of formula (IV), after optional deprotection, is oxidized to obtain an aldehyde of formula (V), which undergoes isomerisation to the compound of formula (I). The subject of the invention are also novel compounds of formulas (II) and (IV).

  本发明涉及一种用于制备公式（I）所示的醛基β-内酰胺化合物的方法，其中P1是H或一个保护基团，该方法可用于依泽替米滨的制备，从公式（II）所示的硝酮化合物出发。硝酮化合物II是通过4-氟苯基羟基胺与OH-保护的4-羟基苯甲醛反应制备的。公式（II）所示的硝酮化合物与公式（III）所示的炔烃化合物反应，形成公式（IV）的化合物，公式（IV）的化合物在可选去保护后，被氧化以获得公式（V）的醛，该醛经过异构化转变为公式（I）的化合物。本发明的主题还包括新颖的公式（II）和（IV）的化合物。
• TETRACYCLIC COMPOUND
  申请人：Kinoshita Kazutomo

  公开号：US20120083488A1

  公开（公告）日：2012-04-05

  A compound represented by the general Formula (I) below, or a salt or solvate thereof, which is useful as an ALK inhibitor, and is useful for prophylaxis or treatment of a disease accompanied by abnormality in ALK, for example, cancer, cancer metastasis, depression or cognitive function disorder: (meanings of the symbols that are included in the formula are as given in the specification).

  一种由下面的一般式（I）表示的化合物，或其盐或溶剂化物，可用作ALK抑制剂，对于伴有ALK异常的疾病的预防或治疗是有用的，例如癌症、癌症转移、抑郁症或认知功能障碍（方程式中包含的符号的含义如规范中所述）。